Monday, 16 Sep 2019

You are here

Reduced Uric Acid from Weight Loss Tied to Triglycerides

Weight loss is one of several nonpharmaceutical interventions to reduce serum urate (SUA) levels and control gout. French researchers examined the role of xanthine oxidase (XO), low-grade inflammation, and weight loss on SUA levels in obese patients.

They examined 154 consecutive patients with severe obesity involved in a bariatric surgery program. Their mean body mass index [BMI] was 47.8 kg/m2 and had a mean 6 month weight loss of 31.3 kg. Weight loss was associated with a modest reduction in SUA levels (-10%) or roughtly a mean loss of 5.5 kg over 6 months. 

The decrease in SUA levels was greatest (-18%) for hyperuricemic patients (n=48). Decreased SUA levels associated with decreased triglycerides levels (p=0.0001) and BMI (p=0.02) but not XO activity, adipokine levels (leptin or adiponectin), insulin resistance, or levels of inflammatory markers.

Weight loss in obese patients was associated with a decrease in both SUA levels and XO activity. However, reductions in SUA levels are partly due to reduction in triglycerides levels. This association strengthens the link between hyperuricemia, gout and the metabolic syndrome.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Modifiable Risk Factors for Hyperuricemia

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia. 

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.